Antimicrobial stewardship during a time of rapid antimicrobial development: Potential impact on industry for future investment

Diagnostic Microbiology and Infectious Disease

Volumn 95, Issue 3, 2019, Pages

  Schulz, Lucas T ^a   Kim, Seok Yeong ^c   Hartsell, Alyssa ^b   Rose, Warren E ^c  

^a University of Wisconsin Health   (United States)

^b Vizient Inc ^*  (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Anti infectives; Antimicrobial stewardship; Industry; Qualified infectious disease product; Resistance, bacteria

Indexed keywords

ANTIINFECTIVE AGENT; AVIBACTAM; CEFTAZIDIME; DALBAVANCIN; ISAVUCONAZOLE; ORITAVANCIN; TEDIZOLID;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DATABASE; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; HOSPITAL BED CAPACITY; INVESTMENT; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT DURATION; UNITED STATES; UNIVERSITY HOSPITAL; DRUG DEVELOPMENT; DRUG UTILIZATION; ECONOMICS; ELECTRONIC HEALTH RECORD; HOSPITAL; HUMAN;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL STEWARDSHIP; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; ELECTRONIC HEALTH RECORDS; HOSPITALS; HUMANS; UNITED STATES;

EID: 85069579854     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2019.06.009     Document Type: Article

References (25)

1. Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy 2006; 26(8): 1078-85.
2. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62(10): e51-77.
3. Bonk ME, Krown H, Matuszewski K, Oinonen M. Potentially inappropriate medications in hospitalized senior patients. Am J Health Syst Pharm 2006; 63(12): 1161-5.
4. Boucher HW, Talbot GH, Benjamin DK, Jr., et al. 10 x '20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56(12): 1685-94.
5. Chambers HF, Bartlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis 2014; 58(11): 1571-6.
6. Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44(2): 159-77.
7. Dodds Ashley E, Davis SL, Heil EL, LaPlante KL, Chahine EB, Bosso JA. Best Care for Patients Achieved Through Multidisciplinary Stewardship. Clin Infect Dis 2018; 67(10): 1637.
8. Forrest GN, Van Schooneveld TC, Kullar R, Schulz LT, Duong P, Postelnick M. Use of Electronic Health Records and Clinical Decision Support Systems for Antimicrobial Stewardship. Clin Infect Dis 2014; 59: S122-S33.
9. Hager N. Hatch, Casey put forward bill to encourage antibiotic innovation. Available at: https://www.finance.senate.gov/chairmans-news/hatch-casey-put-forward-bill-to-encourage-antibiotic-innovation. Accessed May 24, 2019.
10. Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis 2015; 60(9): 1308-16.
11. AKAO Hits New Low, INSY Shifts Focus From Opioids, FDA Nod For Theratechnologies. Available at: https://www.nasdaq.com/article/akao-hits-new-low-insy-shifts-focus-from-opioids-fda-nod-for-theratechnologies-20181106-00043. Accessed November 19, 2018.
12. Humphries RM, Hindler JA. Emerging Resistance, New Antimicrobial Agents. but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape. Clin Infect Dis 2016; 63(1): 83-8.
13. Infectious Diseases Society of A. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50(8): 1081-3.
14. Kullar R, Goff DA, Schulz LT, Fox BC, Rose WE. The “Epic” Challenge of Optimizing Antimicrobial Stewardship: The Role of Electronic Medical Records and Technology. Clin Infect Dis 2013; 57(7): 1005-13.
15. McKenna M. The antibiotics business is broken - but There's a fix. Available at: https://www.wired.com/story/the-antibiotics-business-is-broken-but-theres-a-fix/. Accessed May 21, 2019.
16. Loren G Miller, Another New Antibiotic for Skin Infections and Why Infectious Disease Specialists Are Hypocrites, Clin. Infect. Dis., 68,(7), 1 April 2019, 1223–1224.
17. Ostrowsky B, Banerjee R, Bonomo RA, et al. Infectious Diseases Physicians: Leading the Way in Antimicrobial Stewardship. Clin Infect Dis 2018; 66(7): 995-1003.
18. Outterson K, Rex JH, Jinks T, et al. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov 2016; 15(9): 589-90.
19. Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008; 168(20): 2254-60.
20. Polk RE, Hohmann SF, Medvedev S, Ibrahim O. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis 2011; 53(11): 1100-10.
21. Spellberg B. The future of antibiotics. Crit Care 2014; 18(3): 228.
22. Spellberg B, Bartlett J, Wunderink R, Gilbert DN. Novel approaches are needed to develop tomorrow's antibacterial therapies. Am J Respir Crit Care Med 2015; 191(2): 135-40.
23. Talbot GH, Jezek A, Murray BE, et al. The Infectious Diseases Society of America's 10 x '20 initiative (ten New systemic antibacterial agents FDA-approved by 2020): is 20 x '20 a possibility? Clin Infect Dis 2019 in press.
24. van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 2018; 66(2): 163-71.
25. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7(4): 439-55.